BACKGROUND: @entity1 evaluation of @entity565 severity and medication needs is mostly based on respiratory symptoms and may be influenced by changes in perception of bronchoconstriction-induced sensations. However, the influence of @entity565 medication on the ability to perceive symptoms is still to be documented. This study evaluated the effects of short-term and regular use of @entity10453 on the perception of @entity2710 -induced bronchoconstriction (MIB) in subjects with mild @entity565 , using inhaled @entity3045 on an "as required" basis (n=15), and in subjects with moderate @entity565 , using daily inhaled @entity2715 (mean daily dose, 640 microg; n=15) in addition to @entity3045 to control their @entity565 . METHODS: @entity2710 challenges (MC) were performed at entry into the study, and then before, 1, and 12 h following inhalation of 50 microg of @entity10453 or a placebo, after a 15-day baseline period; and after 4 weeks of twice daily use of those treatments. The measurements were then repeated with the alternate treatment after a 15-day washout period. Finally, a last MC was performed after another 15-day washout period. For each MC, the perception score of bronchoconstriction-associated breathlessness at 20% fall in FEV1 ( @entity33362 ) was evaluated on a modified Borg scale from 0 to 10. RESULTS: Subjects using regular @entity2715 had a higher baseline @entity33362 than those using only @entity3045 (means: 3.06 0.06 and 2.01+/-0.07, p=0.0001). Short- and long-term use of @entity10453 did not change significantly the @entity33362 compared with placebo (p>0.05) in either group (with or without @entity228 ). Although there were some intraindividual variations, mean @entity33362 did not vary significantly throughout the study. CONCLUSION: These observations show that the perception of bronchoconstriction-associated breathlessness is not influenced by regular use of @entity10453 . @entity1 using inhaled corticosteroids show a greater perception of MIB.

Influence of XXXX and @entity10453 on the perception of @entity2710 -induced bronchoconstriction.

@entity1 :: ('9606', 'Species') :: ['Patients', 'Patient'] @entity2715 :: ('MESH:D001507', 'Chemical') :: ['beclomethasone'] @entity565 :: ('MESH:D001249', 'Disease') :: ['asthma'] @entity3045 :: ('MESH:D000420', 'Chemical') :: ['salbutamol'] @entity228 :: ('CHEBI:50858', 'Chemical') :: ['corticosteroid'] @entity33362 :: ('58189', 'Gene') :: ['PS20'] @entity10453 :: ('MESH:C057823', 'Chemical') :: ['salmeterol'] @entity2710 :: ('MESH:D016210', 'Chemical') :: ['methacholine', 'Methacholine']
@entity2715 :: (MESH:D001507,Chemical) :: ['beclomethasone']
